الولايات المتحدة · منصات وبيانات · Morningstar

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

نشره Morningstar · الولايات المتحدة منذ 16 س

Palleon Pharmaceuticals, a clinical-stage biotechnology company developing glycan editing therapeutics for autoimmune disease and cancer, today announced Phase 2 results for…

اقرأ المقال كاملًا على Morningstar سجّل الدخول للحفظ

يعرض MarketNews العنوان والملخص كما نشرتهما الوسيلة الإعلامية. المقال الكامل متوفر على موقع الناشر. (www.morningstar.com)

يستحق القراءة أيضًا

The Motley Fool

Citigroup Forecasts Strong Price Appreciation for Procter & Gamble (NYSE:PG) Stock

Investing.com

Earnings call transcript: Preferred Bank tops Q3 2026 EPS, shares slip premarket

Benzinga

Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026

مشاركة

يستحق القراءة أيضًا

Rogers Communications: 3 Key Takeaways for Long-Term Investors

Trump prepares tariff relief on Canada ahead of midterms - report

Think annuities are a rip-off? Now might be the perfect time to reconsider.

Citigroup Forecasts Strong Price Appreciation for Procter & Gamble (NYSE:PG) Stock

Earnings call transcript: Preferred Bank tops Q3 2026 EPS, shares slip premarket

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030